From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease.

The identification of genetic mutations underlying familial structural heart disease has provided exciting new insights into how alterations in structural components of the cardiomyocyte lead to different forms of cardiomyopathy. Specifically, mutations in components of the sarcomere are frequently associated with hypertrophic cardiomyopathy, whereas mutations in cytoskeletal proteins lead to dilated cardiomyopathy. In addition, extrinsic stresses such as hypertension and valvular disease can produce myocardial remodeling that is very similar to that observed in genetic cardiomyopathy. For myocardial remodeling to occur, changes in gene expression must occur; therefore, changes in contractile function or wall stress must be communicated to the nucleus via signal transduction pathways. The identity of these signaling pathways has become a key question in molecular biology. Numerous signaling molecules have been implicated in the development of hypertrophy and failure, including the beta-adrenergic receptor, G alpha(q) and downstream effectors, mitogen-activated protein kinase pathways, and the Ca(2+)-regulated phosphatase, calcineurin. In the past it has been difficult to discern which signaling molecules actually contributed to disease progression in vivo; however, the development of numerous transgenic and knockout mouse models of cardiomyopathy is now allowing the direct testing of stimulatory and inhibitory molecules in the mouse heart. From this work it has been possible to identify signaling molecules and pathways that are required for different aspects of disease progression in vivo. In particular, a number of signaling pathways have now been identified that may be key regulators of changes in myocardial structure and function in response to mutations in structural components of the cardiomyocyte. Myocardial structure and signal transduction are now merging into a common field of research that will lead to a more complete understanding of the molecular mechanisms that underly heart disease.

[1]  E. Olson,et al.  Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. , 1999, Circulation research.

[2]  M. Quiñones,et al.  Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. , 1995, Circulation.

[3]  E. Kranias,et al.  Phospholamban: a protein coming of age. , 1997, Biochemical and biophysical research communications.

[4]  M. Webb-Peploe,et al.  Echocardiographic left ventricular wall thickness: A poor predictor of the severity of aortic valve stenosis , 1991, Clinical cardiology.

[5]  T. Hewett,et al.  Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. , 1998, The Journal of clinical investigation.

[6]  P. Burch,et al.  Desmin mutation responsible for idiopathic dilated cardiomyopathy. , 1999, Circulation.

[7]  E. Maestrini,et al.  A novel X-linked gene, G4.5. is responsible for Barth syndrome , 1996, Nature Genetics.

[8]  T. Hewett,et al.  A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[9]  H. Hidaka,et al.  Demonstration of a Ca2+/calmodulin dependent protein kinase cascade in the hog heart. , 1998, Biochemical and biophysical research communications.

[10]  G. King,et al.  Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[12]  K. Chien,et al.  Stress Pathways and Heart Failure , 1999, Cell.

[13]  H. Schulman,et al.  The Nuclear δB Isoform of Ca2+/Calmodulin-dependent Protein Kinase II Regulates Atrial Natriuretic Factor Gene Expression in Ventricular Myocytes* , 1997, The Journal of Biological Chemistry.

[14]  G. Fishman,et al.  Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. , 1997, The Journal of clinical investigation.

[15]  I. Ohtsuki,et al.  Ca2+ Sensitization and Potentiation of the Maximum Level of Myofibrillar ATPase Activity Caused by Mutations of Troponin T Found in Familial Hypertrophic Cardiomyopathy* , 1999, The Journal of Biological Chemistry.

[16]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[17]  M. Gardner,et al.  Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. , 1998, Circulation.

[18]  M. Entman,et al.  Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. , 1998, The Journal of clinical investigation.

[19]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[20]  C. Balke,et al.  Alterations in calcium handling in cardiac hypertrophy and heart failure. , 1998, Cardiovascular research.

[21]  H. Hidaka,et al.  Protein kinase C and calmodulin kinase are required for endothelin-stimulated atrial natriuretic factor secretion from primary atrial myocytes. , 1992, The Journal of biological chemistry.

[22]  N. Dzimiri Regulation of β-Adrenoceptor Signaling in Cardiac Function and Disease , 1999 .

[23]  G. Danieli,et al.  Arrhythmogenic right ventricular cardiomyopathy a still underrecognized clinic entity. , 1997, Trends in cardiovascular medicine.

[24]  G. King,et al.  Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. , 1999, Circulation.

[25]  J. Brown,et al.  Rho as a mediator of G protein-coupled receptor signaling. , 1999, Molecular pharmacology.

[26]  R. Doughty,et al.  Beta-adrenergic blocking agents in the treatment of congestive heart failure: mechanisms and clinical results. , 1997, Annual review of medicine.

[27]  S. Vatner,et al.  Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .

[28]  S. Shenolikar,et al.  Protein serine/threonine phosphatases--new avenues for cell regulation. , 1994, Annual review of cell biology.

[29]  Dimitrios Georgakopoulos,et al.  The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation , 1999, Nature Medicine.

[30]  F. Epstein,et al.  Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. , 1991, The New England journal of medicine.

[31]  T. Hewett,et al.  A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[32]  Tak W. Mak,et al.  Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum , 1998, Nature.

[33]  R Hetzer,et al.  Identification and expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. , 1999, Circulation research.

[34]  E. Olson,et al.  Cardiac hypertrophy: sorting out the circuitry. , 1999, Current opinion in genetics & development.

[35]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[36]  E. Erdmann,et al.  Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. , 1998, Journal of molecular and cellular cardiology.

[37]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[38]  T. Tsukahara,et al.  Emerin deficiency at the nuclear membrane in patients with Emery-Dreif uss muscular dystrophy , 1996, Nature Genetics.

[39]  T. Chatila,et al.  Calcium-dependent activation of TNF family gene expression by Ca2+/calmodulin kinase type IV/Gr and calcineurin. , 1999, Journal of immunology.

[40]  L. Leinwand,et al.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.

[41]  G. Crabtree Generic Signals and Specific Outcomes Signaling through Ca2+, Calcineurin, and NF-AT , 1999, Cell.

[42]  A. Lin,et al.  Opposing Effects of Jun Kinase and p38 Mitogen-Activated Protein Kinases on Cardiomyocyte Hypertrophy , 1998, Molecular and Cellular Biology.

[43]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[44]  A. Clerk,et al.  "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. , 1998, Circulation research.

[45]  Anne J. Ridley,et al.  The small GTP-binding protein rac regulates growth factor-induced membrane ruffling , 1992, Cell.

[46]  Michael J. Grusby,et al.  The transcription factor NF-ATc is essential for cardiac valve formation , 1998, Nature.

[47]  T. Hewett,et al.  In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. , 1999, Circulation research.

[48]  C. Aoki,et al.  Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. , 1992, The Journal of biological chemistry.

[49]  P. Sassone-Corsi,et al.  Signaling routes to CREM and CREB: plasticity in transcriptional activation. , 1999, Trends in biochemical sciences.

[50]  Q. Li,et al.  Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. , 1997, The Journal of clinical investigation.

[51]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[52]  S. Green,et al.  Role of βARK in Long-Term Agonist-Promoted Desensitisation of the β2-Adrenergic Receptor , 1998 .

[53]  J. Towbin,et al.  Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. , 1995, Circulation.

[54]  S. Murray,et al.  Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element. , 1995, Circulation research.

[55]  J. Sadoshima,et al.  Angiotensin II and Other Hypertrophic Stimuli Mediated by G Protein–Coupled Receptors Activate Tyrosine Kinase, Mitogen-Activated Protein Kinase, and 90-kD S6 Kinase in Cardiac Myocytes The Critical Role of Ca2+-Dependent Signaling , 1995 .

[56]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[57]  J. Molkentin,et al.  Calcineurin and human heart failure , 1999, Nature Medicine.

[58]  M. Caron,et al.  Beta-adrenergic receptor kinase: primary structure delineates a multigene family. , 1989, Science.

[59]  P. Parker,et al.  Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. , 1994, The Journal of biological chemistry.

[60]  H. Erdjument-Bromage,et al.  FK506 binding protein associated with the calcium release channel (ryanodine receptor). , 1992, The Journal of biological chemistry.

[61]  F. Spinale,et al.  The structure and function of the cardiac myocyte: a review of fundamental concepts. , 1999, The Journal of thoracic and cardiovascular surgery.

[62]  A. Clerk,et al.  Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. , 1997, Cellular signalling.

[63]  J. Guerrero,et al.  Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. , 1999, The Journal of clinical investigation.

[64]  G. Hasenfuss,et al.  Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. , 1995, Circulation.

[65]  S. Snyder,et al.  Calcineurin associated with the inositol 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca2+ flux , 1995, Cell.

[66]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[67]  Y. Hayashizaki,et al.  Identification of the Syrian hamster cardiomyopathy gene. , 1997, Human molecular genetics.

[68]  K. Chien,et al.  Phorbol esters induce immediate-early genes and activate cardiac gene transcription in neonatal rat myocardial cells. , 1990, Journal of molecular and cellular cardiology.

[69]  R. Ferrari,et al.  The role of TNF in cardiovascular disease. , 1999, Pharmacological research.

[70]  A. Clerk,et al.  Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. , 1998, The Biochemical journal.

[71]  J. Frost,et al.  Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy , 1994, The Journal of cell biology.

[72]  P. Simpson,et al.  Differential acute and chronic response of protein kinase C in cultured neonatal rat heart myocytes to alpha 1-adrenergic and phorbol ester stimulation. , 1988, Journal of molecular and cellular cardiology.

[73]  E. A. O'neill,et al.  T cell responses in calcineurin A alpha-deficient mice , 1996, The Journal of experimental medicine.

[74]  R. Schwinger,et al.  Reduced Ca2+-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban Phoshorylation , 1999 .

[75]  G. M. Briggs,et al.  Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. , 1991, The Journal of clinical investigation.

[76]  P. Simpson Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. , 1983, The Journal of clinical investigation.

[77]  R. Lefkowitz,et al.  Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. , 1998, Science.

[78]  M. Takemura,et al.  Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.

[79]  M. Böhm,et al.  Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. , 1994, Circulation research.

[80]  E. Olson,et al.  GATA4: a novel transcriptional regulator of cardiac hypertrophy? , 1997, Circulation.

[81]  E. Maestrini,et al.  Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy , 1994, Nature Genetics.

[82]  H. Schulman,et al.  Identification and characterization of δB-CaM kinase and δC-CaM kinase from rat heart, two new multifunctional Ca2+/calmodulin-dependent protein kinase isoforms , 1994 .

[83]  A. Thorburn,et al.  A Low-Affinity Serum Response Element Allows Other Transcription Factors To Activate Inducible Gene Expression in Cardiac Myocytes , 1999, Molecular and Cellular Biology.

[84]  J Ross,et al.  Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. , 1999, The Journal of clinical investigation.

[85]  Jiahuai Han,et al.  The p38 MAP kinase pathway and its biological function. , 1998, Trends in cardiovascular medicine.

[86]  John W. Adams,et al.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Towbin,et al.  Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23. , 1996, The Journal of clinical investigation.

[88]  K. Chien,et al.  Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. , 1990, The Journal of biological chemistry.

[89]  A. Clerk,et al.  Cellular mechanisms of cardiac hypertrophy , 1998, Journal of Molecular Medicine.

[90]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[91]  L. Karns,et al.  M-CAT, CArG, and Sp1 elements are required for alpha 1-adrenergic induction of the skeletal alpha-actin promoter during cardiac myocyte hypertrophy. Transcriptional enhancer factor-1 and protein kinase C as conserved transducers of the fetal program in cardiac growth. , 1995, The Journal of biological chemistry.

[92]  A. Harding Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. , 1981, Brain : a journal of neurology.

[93]  Jiahuai Han,et al.  Cardiac Hypertrophy Induced by Mitogen-activated Protein Kinase Kinase 7, a Specific Activator for c-Jun NH2-terminal Kinase in Ventricular Muscle Cells* , 1998, The Journal of Biological Chemistry.

[94]  I. Masuda,et al.  A heart-specific increase in cardiotrophin-1 gene expression precedes the establishment of ventricular hypertrophy in genetically hypertensive rats. , 1999, Journal of hypertension.

[95]  D. Leroith,et al.  Insulin-like Growth Factor 1 Inhibits Apoptosis Using the Phosphatidylinositol 3′-Kinase and Mitogen-activated Protein Kinase Pathways* , 1997, The Journal of Biological Chemistry.

[96]  J. Towbin,et al.  X‐Linked Dilated Cardiomyopathy Molecular Genetic Evidence of Linkage to the Duchenne Muscular Dystrophy (Dystrophin) Gene at the Xp21 Locus , 1993, Circulation.

[97]  J. Brown,et al.  Dissociation of p44 and p42 Mitogen-activated Protein Kinase Activation from Receptor-induced Hypertrophy in Neonatal Rat Ventricular Myocytes (*) , 1996, The Journal of Biological Chemistry.

[98]  A. Kong,et al.  A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1–1q1 , 1994, Nature Genetics.

[99]  P. Allen,et al.  Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. , 1992, Circulation research.

[100]  S. Vatner,et al.  Effects of chronic beta-adrenergic receptor stimulation in mice. , 1997, Journal of molecular and cellular cardiology.

[101]  F. Muntoni,et al.  Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. , 1993, The New England journal of medicine.

[102]  L. Fananapazir,et al.  Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. , 1995, The Journal of clinical investigation.

[103]  Mark A Sussman,et al.  Prevention of cardiac hypertrophy in mice by calcineurin inhibition. , 1998, Science.

[104]  S. Houser,et al.  Cellular basis of contractile derangements of hypertrophied feline ventricular myocytes. , 1997, Journal of molecular and cellular cardiology.

[105]  T. Borg,et al.  Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. , 1999, Circulation research.

[106]  W. Schmitz,et al.  Activity of cAMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. , 1999, Cardiovascular research.

[107]  Y. Yazaki,et al.  Mechanical stretch activates the stress‐activated protein kinase in cardiac myocytes , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[109]  R. Prywes,et al.  p38 Mitogen-activated Protein Kinase Mediates the Transcriptional Induction of the Atrial Natriuretic Factor Gene through a Serum Response Element , 1998, The Journal of Biological Chemistry.

[110]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[111]  S. Ogawa,et al.  Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. , 1999, Circulation research.

[112]  Y. Goto,et al.  A new mtDNA mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). , 1991, Biochimica et biophysica acta.

[113]  E. Hoffman,et al.  Heart involvement in muscular dystrophies due to sarcoglycan gene mutations , 1999, Muscle & nerve.

[114]  G. Dorn,et al.  Sustained in vivo cardiac protection by a rationally designed peptide that causes ɛ protein kinase C translocation , 1999 .

[115]  F. Muntoni,et al.  Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy , 1999, Nature Genetics.

[116]  R. Lang,et al.  Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. , 1998, The Journal of clinical investigation.

[117]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[118]  W. Lederer,et al.  Sarcoplasmic reticulum in heart failure: central player or bystander? , 1998, Cardiovascular research.

[119]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[120]  Y. Zou,et al.  Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. , 1997, Circulation research.

[121]  H. Youn,et al.  Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. , 1998, Immunity.

[122]  K. Chien,et al.  Rho Is Required for Gαq and α1-Adrenergic Receptor Signaling in Cardiomyocytes , 1996, The Journal of Biological Chemistry.

[123]  G. Danieli,et al.  A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. , 1995, Human molecular genetics.

[124]  C. Hall,et al.  Regulation of Phosphorylation Pathways by p21 GTPases , 1996 .

[125]  A. Thorburn Ras activity is required for phenylephrine-induced activation of mitogen-activated protein kinase in cardiac muscle cells. , 1994, Biochemical and biophysical research communications.

[126]  Y. Murakami,et al.  Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[127]  John Calvin Reed,et al.  Bcl‐2, Raf‐1 and mitochondrial regulation of apoptosis , 1998, BioFactors.

[128]  H. Katus,et al.  Frequency and phenotypes of familial dilated cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[129]  J A Osborne,et al.  Familial dilated cardiomyopathy locus maps to chromosome 2q31. , 1999, Circulation.

[130]  L. Goatley,et al.  A viral mechanism for inhibition of the cellular phosphatase calcineurin. , 1998, Science.

[131]  M. Martone,et al.  Chronic Phospholamban–Sarcoplasmic Reticulum Calcium ATPase Interaction Is the Critical Calcium Cycling Defect in Dilated Cardiomyopathy , 1999, Cell.

[132]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[133]  G. Danieli,et al.  ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. , 1997, Genomics.

[134]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[135]  M. Caron,et al.  Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[136]  L. Leinwand,et al.  Identification of a cis-acting regulatory element conferring inducibility of the atrial natriuretic factor gene in acute pressure overload. , 1997, The Journal of clinical investigation.

[137]  K. Chien,et al.  The Low Molecular Weight GTPase Rho Regulates Myofibril Formation and Organization in Neonatal Rat Ventricular Myocytes , 1998, The Journal of Biological Chemistry.

[138]  K. Campbell,et al.  The sarcoglycan complex in limb-girdle muscular dystrophy. , 1998, Current opinion in neurology.

[139]  N. Ahn,et al.  Inhibition of a signaling pathway in cardiac muscle cells by active mitogen-activated protein kinase kinase. , 1995, Molecular biology of the cell.

[140]  J. Heath,et al.  Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy , 1996, The Journal of Biological Chemistry.

[141]  R. Hajjar,et al.  Effect of protein kinase C activation on sarcoplasmic reticulum function and apparent myofibrillar Ca2+ sensitivity in intact and skinned muscles from normal and diseased human myocardium. , 1990, Circulation research.

[142]  T. Chatila,et al.  Cyclosporin A‐sensitive induction of the Epstein‐Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member , 1997, The EMBO journal.

[143]  F. Baas,et al.  Mapping of the locus for X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. , 1991, American journal of human genetics.

[144]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[145]  E. Neer,et al.  Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[146]  E. Homsher,et al.  Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. , 1996, The Journal of clinical investigation.

[147]  L. Leinwand,et al.  Mice Expressing Mutant Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy , 1996, Molecular medicine.

[148]  T. Doetschman,et al.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. , 1994, Circulation research.

[149]  T. McIntosh,et al.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.

[150]  F. Giordano,et al.  Antisense fosB RNA inhibits thrombin-induced hypertrophy in cultured pulmonary arterial smooth muscle cells. , 1998, Circulation.

[151]  Richard Treisman,et al.  Signal-Regulated Activation of Serum Response Factor Is Mediated by Changes in Actin Dynamics , 1999, Cell.

[152]  R. Venema,et al.  Protein kinase C-mediated phosphorylation of troponin I and C-protein in isolated myocardial cells is associated with inhibition of myofibrillar actomyosin MgATPase. , 1993, The Journal of biological chemistry.

[153]  A. Nogami,et al.  Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. , 1993, The Journal of clinical investigation.

[154]  H. Schunkert Polymorphism of the angiotensin-converting enzyme gene and cardiovascular disease , 1997, Journal of Molecular Medicine.

[155]  T. Rebbeck,et al.  Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. , 1999, Circulation.

[156]  M. Rudnicki,et al.  Severe cardiomyopathy in mice lacking dystrophin and MyoD. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[157]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[158]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[159]  H. Watkins,et al.  Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[160]  Y. Fujio,et al.  Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. , 1997, Journal of molecular and cellular cardiology.

[161]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[162]  P. Sugden,et al.  Signaling in myocardial hypertrophy: life after calcineurin? , 1999, Circulation research.

[163]  K. Chien,et al.  Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. , 1996, Development.

[164]  W. Koch,et al.  Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.

[165]  A. Thorburn,et al.  MAP kinase‐ and Rho‐dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells , 1997, The EMBO journal.

[166]  R. Frank,et al.  Evidence of apoptosis in arrhythmogenic right ventricular dysplasia. , 1996, The New England journal of medicine.

[167]  F. McCormick,et al.  A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[168]  A. Tajik,et al.  The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. , 1992, The New England journal of medicine.

[169]  H. Schulman,et al.  The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. , 1995, Annual review of physiology.

[170]  H. Kung,et al.  Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.

[171]  J. Seidman,et al.  Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. , 1999, The New England journal of medicine.

[172]  D. Kass,et al.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.

[173]  Anthony J. Muslin,et al.  RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.

[174]  L. Kunkel,et al.  Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy , 1995, Science.

[175]  Hao Ren,et al.  Regulation of the Calmodulin-stimulated Protein Phosphatase, Calcineurin* , 1998, The Journal of Biological Chemistry.

[176]  H. Watkins,et al.  Sudden death due to troponin T mutations. , 1997, Journal of the American College of Cardiology.

[177]  Hammond Hk,et al.  Beta-adrenergic receptors and receptor signaling in heart failure. , 1999 .

[178]  S. Snyder,et al.  Cain, A Novel Physiologic Protein Inhibitor of Calcineurin* , 1998, The Journal of Biological Chemistry.

[179]  D. Zechner,et al.  A Role for the p38 Mitogen-activated Protein Kinase Pathway in Myocardial Cell Growth, Sarcomeric Organization, and Cardiac-specific Gene Expression , 1997, The Journal of cell biology.

[180]  C. Marshall,et al.  Hypertrophic Agonists Stimulate the Activities of the Protein Kinases c-Raf and A-Raf in Cultured Ventricular Myocytes (*) , 1995, The Journal of Biological Chemistry.

[181]  A. Hata,et al.  Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. , 1997, American heart journal.

[182]  V. Fuster,et al.  The natural history of idiopathic dilated cardiomyopathy. , 1981, The American journal of cardiology.

[183]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[184]  M. Keating,et al.  Mapping a cardiomyopathy locus to chromosome 3p22-p25. , 1996, The Journal of clinical investigation.

[185]  J C Reed,et al.  Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. , 1999, Science.

[186]  S. Humphries,et al.  Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[187]  P. Sugden,et al.  Endothelin‐1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes , 1993, FEBS letters.

[188]  P. Simpson β-Protein Kinase C and Hypertrophic Signaling in Human Heart Failure , 1999 .

[189]  S. Powers,et al.  HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. , 1993, The Journal of biological chemistry.

[190]  P. Sugden,et al.  The Mitogen-activated Protein Kinase Kinase MEK1 Stimulates a Pattern of Gene Expression Typical of the Hypertrophic Phenotype in Rat Ventricular Cardiomyocytes (*) , 1995, The Journal of Biological Chemistry.

[191]  Y. Zou,et al.  Rho family small G proteins play critical roles in mechanical stress-induced hypertrophic responses in cardiac myocytes. , 1999, Circulation research.

[192]  M. Yaffe,et al.  Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. , 1999, Science.

[193]  J. Lorenz,et al.  Abnormal Cardiac Structure and Function in Mice Expressing Nonphosphorylatable Cardiac Regulatory Myosin Light Chain 2* , 1999, The Journal of Biological Chemistry.

[194]  A. Clerk,et al.  Stimulation of phosphatidylinositol hydrolysis, protein kinase C translocation, and mitogen-activated protein kinase activity by bradykinin in rat ventricular myocytes: dissociation from the hypertrophic response. , 1996, The Biochemical journal.

[195]  H. Singer,et al.  Identification of novel isoforms of the delta subunit of Ca2+/calmodulin-dependent protein kinase II. Differential expression in rat brain and aorta. , 1993, The Journal of biological chemistry.

[196]  M. Komajda,et al.  Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. , 1998, European heart journal.

[197]  M. Martone,et al.  Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy , 1999, Nature Medicine.

[198]  L. Mestroni,et al.  A mutation in the dystrophin gene selectively affecting dystrophin expression in the heart. , 1995, The Journal of clinical investigation.

[199]  L. Mestroni,et al.  A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. , 1996, Genomics.

[200]  D. Wallace,et al.  Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation , 1990, Cell.

[201]  K. Sliwa,et al.  Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[202]  M. Yacoub,et al.  Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. , 1996, Circulation.

[203]  K. Mikoshiba,et al.  Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. , 1995, Circulation.

[204]  B. Pitt,et al.  Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. , 1986, American heart journal.

[205]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[206]  K. Chien,et al.  Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis via a Mitogen-activated Protein Kinase-dependent Pathway , 1997, The Journal of Biological Chemistry.

[207]  W. Lederer,et al.  Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. , 1997, Science.

[208]  R. Hajjar,et al.  Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. , 1998, The Journal of clinical investigation.

[209]  A. Clerk,et al.  Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. , 1996, The Biochemical journal.

[210]  J. Towbin,et al.  The role of cytoskeletal proteins in cardiomyopathies. , 1998, Current opinion in cell biology.

[211]  G. Pavlath,et al.  Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. , 1998, Molecular biology of the cell.

[212]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.

[213]  Pascale Richard,et al.  Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy , 1998, Journal of Molecular Medicine.

[214]  M. Murakami,et al.  Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. , 1995, American heart journal.

[215]  M. Davies,et al.  A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy , 1999, Heart.

[216]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[217]  M. Marcus,et al.  The heart in hypertension. , 1992, The New England journal of medicine.

[218]  J Ross,et al.  Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.

[219]  M. Komajda,et al.  The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. , 1997, Journal of molecular and cellular cardiology.

[220]  K. Chien,et al.  The MEKK-JNK Pathway Is Stimulated by α1-Adrenergic Receptor and Ras Activation and Is Associated with in Vitroand in Vivo Cardiac Hypertrophy* , 1997, The Journal of Biological Chemistry.

[221]  M. Pericak-Vance,et al.  Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. , 1997, American journal of human genetics.

[222]  J. Sanes,et al.  ε-Sarcoglycan Replaces α-Sarcoglycan in Smooth Muscle to Form a Unique Dystrophin-Glycoprotein Complex* , 1999, The Journal of Biological Chemistry.

[223]  J. Ross,et al.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[224]  R. Brady,et al.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.

[225]  C. Widmann,et al.  MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases? , 1997, Current opinion in genetics & development.

[226]  S. Lehnart,et al.  Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. , 1999, Circulation.

[227]  H Fujisawa,et al.  Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. , 1989, The Journal of biological chemistry.

[228]  L. Van Aelst,et al.  Rho GTPases and signaling networks. , 1997, Genes & development.

[229]  R. Lefkowitz,et al.  Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.

[230]  G. Boivin,et al.  Molecular and Physiological Effects of Overexpressing Striated Muscle β-Tropomyosin in the Adult Murine Heart (*) , 1995, The Journal of Biological Chemistry.

[231]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[232]  T. Toyofuku,et al.  Molecular regulation of phospholamban function and expression. , 1998, Trends in cardiovascular medicine.

[233]  A. Clerk,et al.  Regulation of mitogen-activated protein kinase cascades in the heart. , 1998, Advances in enzyme regulation.

[234]  P. Sugden,et al.  Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. , 1996, Circulation research.

[235]  Minoru Hongo,et al.  MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.

[236]  H. Okamura,et al.  Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. , 1998, Molecular cell.

[237]  M. Böhm,et al.  Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. , 1995, Circulation.

[238]  R. Kloner,et al.  Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine. , 1996, Circulation.

[239]  T. Kishimoto,et al.  Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[240]  S. Donnelly,et al.  Familial Hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. , 1994, The Journal of clinical investigation.

[241]  G Thiene,et al.  The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. , 1994, Human molecular genetics.

[242]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[243]  E. Olson,et al.  Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? , 1999, Circulation research.

[244]  K. Tanaka,et al.  A requirement for the rac1 GTPase in the signal transduction pathway leading to cardiac myocyte hypertrophy. , 1998, The Journal of clinical investigation.

[245]  R. Krams,et al.  AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. , 1998, Hypertension.

[246]  W. MacLellan,et al.  Death by design. Programmed cell death in cardiovascular biology and disease. , 1997, Circulation research.

[247]  C. Marshall,et al.  Regulation of Ras·GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester , 1999, The Journal of Biological Chemistry.

[248]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[249]  O. Ornatsky,et al.  Immunolocalization of meta-vinculin in human smooth and cardiac muscles , 1988, The Journal of cell biology.

[250]  M. Wilkinson,et al.  SAPKs and transcription factors do the nucleocytoplasmic tango. , 1998, Genes & development.

[251]  Y. Zou,et al.  Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[252]  M. Lopez-Ilasaca Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. , 1998, Biochemical pharmacology.

[253]  R. Bonow,et al.  Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.

[254]  S. Houser,et al.  Function of the cardiac myocyte in the conundrum of end-stage, dilated human heart failure. , 1999, Circulation.

[255]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[256]  G. Dorn,et al.  Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice , 1999 .

[257]  G. Dorn,et al.  Transgenic Gαq overexpression induces cardiac contractile failure in mice , 1997 .

[258]  K. Chien,et al.  Ventricular Expression of a MLC-2v-ras Fusion Gene Induces Cardiac Hypertrophy and Selective Diastolic Dysfunction in Transgenic Mice (*) , 1995, The Journal of Biological Chemistry.

[259]  D. Mann,et al.  Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes , 1995 .

[260]  M. B. Perryman,et al.  Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy , 1993, The Lancet.

[261]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[262]  M. Patton,et al.  Cardiologic Abnormalities in Noonan Syndrome: Phenotypic Diagnosis and Echocardiographic Assessment of 118 Patients , 1993, Journal of the American College of Cardiology.

[263]  A. Clerk,et al.  Stimulation of the p38 Mitogen-activated Protein Kinase Pathway in Neonatal Rat Ventricular Myocytes by the G Protein–coupled Receptor Agonists, Endothelin-1 and Phenylephrine: A Role in Cardiac Myocyte Hypertrophy? , 1998, The Journal of cell biology.

[264]  B. Lowes,et al.  Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. , 1996, Circulation.

[265]  S. Izumo,et al.  Apoptosis: basic mechanisms and implications for cardiovascular disease. , 1998, Circulation research.

[266]  L. Mestroni,et al.  Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. , 1995, American journal of human genetics.

[267]  K. Campbell,et al.  Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy , 1999, Cell.

[268]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.